Themis Medicare Limited has informed the Exchange regarding Appointment of Nagraj Mogaveera as Company Secretary & Compliance Officer of the company w.e.f. February 14, 2026.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare's board, at its February 13, 2026 meeting, approved the unaudited Q3 FY26 (quarter ended Dec 31, 2025) financial results. Standalone revenue came in at Rs 9,013.32 lakhs (down from Rs 9,380.63 lakhs YoY), with a net profit of Rs 457.81 lakhs versus Rs 308.12 lakhs last year; however, the nine-month standalone result remained in loss at Rs (1,615.11) lakhs. Consolidated Q3 net profit surged to Rs 1,009.36 lakhs (from Rs 51.93 lakhs YoY), helped by share of profit from associates. The board accepted the resignation of Company Secretary and KMP Mr. Pradeep M. Chandan (effective Feb 13, 2026) due to other professional commitments, and appointed Mr. Nagraj Mogaveera (currently Deputy CS at the company) as Interim Company Secretary and Compliance Officer from Feb 14, 2026.
Q3 consolidated profitability showed a strong rebound, but the nine-month picture remains in the red, so near-term sentiment depends on whether the turnaround sustains. The proposed promoter preferential allotment could lead to mild dilution for existing public shareholders once priced, while the GTBL inter-se transfer is neutral since it stays within the promoter group and does not change control.